Paeds Vivas · haematology-oncology-and-transfusion
G6PD deficiency and enzymopathies: Viva
Branching clinical structured oral on glucose-6-phosphate dehydrogenase deficiency: recognition of an acute haemolytic crisis in a boy after fava beans, the mechanism of oxidative haemolysis and the blood film interpretation, the critical timing pitfall of the enzyme assay, the transfusion decision, and the lifelong trigger-avoidance counselling and pharmacogenetic prescribing under the 2023 Clinical Pharmacogenetics Implementation Consortium guideline.
On this page
Study tools
Target exams
Branch 1: Recognising the problem and the mechanism
The candidate should immediately recognise this as a direct-antiglobulin-test-negative intravascular haemolysis in a boy of African ancestry after a viral trigger, which places G6PD deficiency at the top of the differential. The combination of sudden jaundice, dark urine, pallor, a high reticulocyte count, a negative direct antiglobulin test, and bite cells with Heinz bodies is the blood-film signature of oxidative haemolysis. The candidate should state the diagnosis aloud as the problem representation and confirm that the film findings are pathognomonic when combined with the negative direct antiglobulin test. [1]
The examiner will probe the mechanism. The candidate should explain that G6PD generates NADPH through the pentose phosphate pathway, that NADPH keeps glutathione reduced, and that reduced glutathione neutralises the oxidants generated in the red cell. In deficiency, oxidants denature haemoglobin into Heinz bodies, the spleen pits them out to form bite cells, and the membrane lyses. The candidate should explain why red cells are uniquely vulnerable, namely that they have no nucleus and cannot replace the deficient enzyme, so the oldest cells with the least residual activity are lysed first. [1][2]
References4ShowHide
- [1]Cappellini MD, Fiorelli G Glucose-6-phosphate dehydrogenase deficiency. Lancet, 2008.PMID 18177777
- [2]Luzzatto L, Seneca E G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol, 2014.PMID 24372186
- [6]Gammal RS, Pirmohamed M, Somogyi AA, Morris SA, et al Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther, 2023.PMID 36049896
- [9]Lau HK, Li CH, Lee AC Acute massive haemolysis in children with glucose-6-phosphate dehydrogenase deficiency. Hong Kong Med J, 2006.PMID 16603783